T cell receptors
The present invention relates to T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the MAGE-A4 protein. The TCRs of the invention demonstrate excellent specificity profiles for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells harbouring expression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the invention.
1. A method for treating cancer in a subject, comprising administering to the subject a T cell comprising a T cell receptor (TCR) or one or polynucleotides encoding the TCR, wherein the TCR comprises an alpha chain variable domain (Vα) comprising complementarity determining regions (CDRs) Vα CDR1, Vα CDR2 and Vα CDR3 and a beta chain variable domain (Vβ) comprising CDRs Vβ CDR1, Vβ CDR2 and Vβ CDR3, wherein:
the Vα CDR1 comprises amino acid residues 28-33 of SEQ ID NO: 3;
the Vα CDR2 comprises amino acid residues 48-53 of SEQ ID NO: 3, 7 or 8;
the Vα CDR3 comprises amino acid residues 91-105 of SEQ ID NO: 3;
the Vβ CDR1 comprises amino acid residues 46-50 of SEQ ID NO: 9;
the Vβ CDR2 comprises amino acid residues 68-72 of SEQ ID NO: 9; and
the Vβ CDR3 comprises amino acid residues 110-123 of SEQ ID NO: 9, and
wherein the subject has a cancer cell that expresses a melanoma-associated antigen (MAGE) A4 protein.
2. The method of claim 1 , wherein the alpha chain variable domain comprises the amino acid sequence of SEQ ID NO: 3, 7 or 8, and the beta variable domain comprises the amino acid sequence of SEQ ID NO: 9.
3. The method of claim 2 , wherein the T cell comprises the one or more polynucleotides.
4. The method of claim 1 , wherein the alpha chain variable domain comprises the amino acid sequence of SEQ ID NO: 3, and the beta variable domain comprises the amino acid sequence of SEQ ID NO: 9.
5. The method of claim 4 , wherein the T cell comprises the one or more polynucleotides.
6. The method of claim 1 , wherein the alpha chain variable domain comprises the amino acid sequence of SEQ ID NO: 7, and the beta variable domain comprises the amino acid sequence of SEQ ID NO: 9.
7. The method of claim 6 , wherein the T cell comprises the one or more polynucleotides.
8. The method of claim 1 , wherein the alpha chain variable domain comprises the amino acid sequence of SEQ ID NO: 8, and the beta variable domain comprises the amino acid sequence of SEQ ID NO: 9.
9. The method of claim 8 , wherein the T cell comprises the one or more polynucleotides.
10. The method of claim 1 , wherein the TCR is an alpha-beta heterodimer, having an alpha chain TRAV10+TRAC constant domain sequence and a beta chain TRBV24-1+TRBC-2 constant domain sequence.
11. The method of claim 1 , wherein the TCR is in a single chain format of the type Vα-L-Vβ, Vβ-L-Vα, Vα-Cα-L-Vβ, or Vα-L-Vβ-Cβ, wherein Vα and Vβ are TCR α and β variable regions respectively, Cα and Cβ are TCR α and β constant regions respectively, and L is a linker sequence.
12. The method of claim 1 , wherein the T cell comprises the one or more polynucleotides.